DeLene BeelandFirst in human clinical trials of the AnAPN1 malaria transmission-blocking vaccine
Former director of the PATH Malaria Vaccine Initiative, Christian Loucq, M.D., says it is exciting to see Dinglasan's concept moving toward a clinical trial. "There are very interesting issues to be addressed in this project which span the technical, immunological, strategic, regulatory and behavioral," says Dr. Loucq, who also formerly directed the International Vaccine Institute. "A transmission-blocking vaccine would be the most elegant solution to the problem of malaria."
Jasmine B. Ayers, Heather G. Coatsworth, Seokyoung Kang, Rhoel R. Dinglasan* & Lei Zhou* (*co-corresponding authors) Clustered rapid induction of apoptosis limits ZIKV and DENV-2 proliferation in the midguts of Aedes aegypti
Jasmine's 1st first-author paper (Yay Jasmine!) that dissects very early innate immune defense mechanisms of mosquito vectors following infection with flaviviruses.